Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019

Wenyi Peng,Hao Wu,Yan Tan,Mei Li,Dachun Yang,Shuang Li
DOI: https://doi.org/10.1016/j.lfs.2020.118496
IF: 6.78
2020-12-01
Life Sciences
Abstract:<p>The infection epidemic event of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was formally declared a pandemic by World Health Organization on March 11th, 2020. Corona Virus Disease 2019 (COVID-19) is caused by SARS-CoV-2, a new type of coronavirus, which has high contagion and mainly causes respiratory symptoms. With the increase in confirmed cases, however, the infection symptoms turn to be diverse with secondary or first clinical symptoms relating to damage of the cardiovascular system and changes of myocardial enzyme spectrum, cardiac troponin I, electrocardiogram, cardiac function. The occurrence of extra-pulmonary manifestations, including immediately and long-term damage, means that the overall health burden caused by SARS-CoV-2 infection may be under-estimated because COVID-19 patients developed cardiovascular system injury are more likely to become serious. The factors such as directly pathogen-mediated damage to cardiomyocytes, down-regulated angiotensin-converting enzyme 2 (ACE2) expression, excessive inflammatory response, hypoxia and adverse drug reaction, are closely related to the occurrence and development of the course of COVID-19. In combination with recently published medical data of patients having SARS-CoV-2 infection and the latest studies, the manifestations of damage to cardiovascular system by COVID-19, possible pathogenic mechanisms and advances of the treatment are proposed in this article.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?
This paper aims to explore the mechanisms of myocardial injury in patients with Coronavirus Disease 2019 (COVID - 19) and its treatment methods. Specifically, the paper focuses on the following aspects: 1. **Acute Myocardial Injury**: - The paper points out that acute myocardial injury is not rare in confirmed cases of COVID - 19. Early reports showed that among the first 41 confirmed cases, 5 cases (12%) had acute myocardial injury, manifested as an increase in high - sensitivity cardiac troponin I (hs - cTnI) levels. Four of these patients were severely ill. - Subsequent studies found that the levels of creatine kinase (CK) and lactate dehydrogenase (LDH) in COVID - 19 patients increased by 13% and 76% respectively. In addition, the levels of myocardial markers such as CK - MB and hs - cTnI in severely ill patients increased significantly, suggesting that severely ill patients are more likely to develop acute myocardial injury. 2. **Chronic Cardiac Damage**: - Long - term follow - up data show that SARS patients have an increased risk of cardiovascular diseases within 10 years after recovery. Similarly, recent studies have shown that cardiac involvement persists in recovered COVID - 19 patients, suggesting that the virus may have a long - term impact on the heart. 3. **SARS - CoV - 2 Infection Complicated with Underlying Cardiovascular Diseases**: - The paper mentions that some SARS - CoV - 2 patients have chronic underlying diseases, especially cardiovascular diseases and diabetes, and these patients are more likely to develop severe illness after infection. Reports from the Chinese Center for Disease Control and Prevention show that the mortality rate of patients with underlying diseases is significantly higher than that of patients without underlying diseases. 4. **Possible Mechanisms of Myocardial Injury Caused by SARS - CoV - 2**: - **Direct Myocardial Infection**: SARS - CoV - 2 may directly attack cardiomyocytes by binding to angiotensin - converting enzyme 2 (ACE2). - **Down - regulation of ACE2 Expression**: The down - regulation of ACE2 expression in cardiac tissue may lead to a decrease in protective angiotensin 1 - 7 (Ang 1 - 7), thereby exacerbating the development of cardiovascular diseases. - **Cytokine Storm and Autoimmune Response**: SARS - CoV - 2 infection can trigger a cytokine storm, leading to acute lung injury, acute respiratory distress syndrome (ARDS), and multi - organ dysfunction. - **Other Mechanisms**: Hypoxemia, side effects of antiviral drugs, and patients' psychological stress may also cause myocardial injury. 5. **Treatment Strategies**: - **Antiviral Treatment**: Antiviral drugs such as α - interferon, lopinavir/ritonavir, ribavirin, chloroquine, and arbidol are recommended. - **ACE2 as a Potential Treatment Target**: Protect the lungs by blocking the binding of SARS - CoV - 2 to ACE2, inhibiting ACE, or using recombinant human ACE2 protein. In conclusion, this paper attempts to comprehensively analyze the mechanisms of myocardial injury in COVID - 19 patients and propose corresponding treatment strategies, hoping to provide guidance for clinical practice.